纳米药物治疗丙型肝炎的现状和未来。

Nanomedicine (London, England) Pub Date : 2025-07-01 Epub Date: 2025-06-26 DOI:10.1080/17435889.2025.2518912
Drue Julien, Horacio Bach
{"title":"纳米药物治疗丙型肝炎的现状和未来。","authors":"Drue Julien, Horacio Bach","doi":"10.1080/17435889.2025.2518912","DOIUrl":null,"url":null,"abstract":"<p><p>Despite recent advances in hepatitis C treatment, the disease remains a significant global health burden, with an estimated 1 million new infections in 2022. Upon infection, the disease will progress to chronic infection, leading to cirrhosis, fibrosis, hepatocellular carcinoma, and end-stage liver disease. Although treatments (Direct-Acting Antiretrovirals) are available, they cannot completely clear the virus. In this review, we summarized the current therapies used to treat hepatitis C, followed by an analysis of the future application of nanomedicine to combat this disease. We compile information related to gene silencing, the nanodelivery of specific drugs, and the trials associated with vaccine development. Although many studies have been successful in animal models, further research is needed to develop a cure or vaccine.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1589-1601"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233889/pdf/","citationCount":"0","resultStr":"{\"title\":\"Current treatments and the future of nanomedicine in hepatitis C.\",\"authors\":\"Drue Julien, Horacio Bach\",\"doi\":\"10.1080/17435889.2025.2518912\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Despite recent advances in hepatitis C treatment, the disease remains a significant global health burden, with an estimated 1 million new infections in 2022. Upon infection, the disease will progress to chronic infection, leading to cirrhosis, fibrosis, hepatocellular carcinoma, and end-stage liver disease. Although treatments (Direct-Acting Antiretrovirals) are available, they cannot completely clear the virus. In this review, we summarized the current therapies used to treat hepatitis C, followed by an analysis of the future application of nanomedicine to combat this disease. We compile information related to gene silencing, the nanodelivery of specific drugs, and the trials associated with vaccine development. Although many studies have been successful in animal models, further research is needed to develop a cure or vaccine.</p>\",\"PeriodicalId\":74240,\"journal\":{\"name\":\"Nanomedicine (London, England)\",\"volume\":\" \",\"pages\":\"1589-1601\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233889/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nanomedicine (London, England)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/17435889.2025.2518912\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2025.2518912","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/26 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

尽管丙型肝炎治疗最近取得了进展,但该疾病仍然是一个重大的全球卫生负担,估计到2022年将有100万新感染病例。一旦感染,疾病将发展为慢性感染,导致肝硬化、纤维化、肝细胞癌和终末期肝病。虽然有治疗方法(直接作用的抗逆转录病毒药物),但它们不能完全清除病毒。在这篇综述中,我们总结了目前用于治疗丙型肝炎的治疗方法,然后分析了纳米药物在对抗这种疾病中的未来应用。我们汇编了与基因沉默、特定药物的纳米递送以及与疫苗开发相关的试验相关的信息。尽管许多研究在动物模型中取得了成功,但还需要进一步研究以开发一种治疗方法或疫苗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Current treatments and the future of nanomedicine in hepatitis C.

Despite recent advances in hepatitis C treatment, the disease remains a significant global health burden, with an estimated 1 million new infections in 2022. Upon infection, the disease will progress to chronic infection, leading to cirrhosis, fibrosis, hepatocellular carcinoma, and end-stage liver disease. Although treatments (Direct-Acting Antiretrovirals) are available, they cannot completely clear the virus. In this review, we summarized the current therapies used to treat hepatitis C, followed by an analysis of the future application of nanomedicine to combat this disease. We compile information related to gene silencing, the nanodelivery of specific drugs, and the trials associated with vaccine development. Although many studies have been successful in animal models, further research is needed to develop a cure or vaccine.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信